We have developed a direct immuno¯uorescence technique utilising chelates of the lanthanide ions europium and terbium conjugated to monoclonal IgGs (Mabs) against prostate-speci®c antigen (PSA) and alpha-1-antichymotrypsin (ACT) for the detection and quanti®cation on the same tissue section. Strong signals without disturbance from tissue auto¯uorescence were demonstrated in paraf®n sections of ten benign and six malignant prostate tissue specimens. The signal intensity increased linearly with the amount of labelled Mab until epitope saturation began. The highest concentrations of bound IgG in tissue sections were 27.3 fmolapixel for ACT and 7.2 for PSA. Time-resolved¯uorescence imaging (TRFI) offers an attractive method for histochemical studies based on speci®c and quantitative detection of¯uorescent lanthanide chelates.
Introduction
The lanthanide ions, europium (Eu) and terbium (Tb) are particularly suitable as immunolabels, since they have been shown to form inherently¯uorescent chelates with long decay times, large Stokes' shifts and sharp emission peaks. 1, 2 These labels have been successfully introduced in time-resolved¯uorescence in several immunoassays, 3 ± 5 and in DNA hybridisation assays. 6 ± 8 The generation of more photostabile lanthanide chelates made them suitable to use in histochemistry for timeresolved¯uorescence imaging (TFRI). 2,9 ± 13 Moreover, uorescent lanthanide chelates may provide a valuable tool for histochemical studies due to their long decay time, around 1000 ms, which enables a speci®c signal detection with an exclusion of auto¯uorescence with a known decay time less than 100 ns. 2 Recently we described the use of TRFI in indirect immunohistochemistry (IHC) of prostate tissue specimens for localisation and quanti®cation of prostatespeci®c antigen (PSA). 14 PSA is produced by a majority of prostate tumour cells and is the most important and speci®c marker for detection and follow-up in prostate cancer (CAP) today. 15 ± 17 In blood, PSA is predominantly complexed to alpha-1-antichymotrypsin (ACT) but a small proportion occurs in a free, non-complexed form. Immuno¯uorometric measurements of free vs total PSA in serum have been shown to signi®cantly increase diagnostic speci®city in the early detection of CAP by serum PSA measurements, as the proportion of PSA complexed to ACT in serum is signi®cantly higher in CAP than in benign prostatic hyperplasia (BPH). 18 ± 23 PSA and ACT have been localised and shown to be expressed in the same cells of the benign and malignant prostate epithelium using conventional IHC and in situ hybridisation (ISH) of mRNA in tissue sections. 24, 25 By means of previously well characterised monoclonal anti-PSA and anti-ACT IgGs our aim now was to develop a direct immunohistochemical TRFI method for speci®c detection and quanti®cation of PSA and ACT in the same prostate tissue sections. We also intended to study if there are any differences in concentrations of PSA and ACT in a small series of benign and malignant tissue sections that warrant extended studies.
Materials and methods

Tissues
Human prostate specimens from ten patients with BPH were collected at transurethral resection of the prostate (TURP) (n 6) or at open prostatectomy (n 4) at the Department of Urology, Malmo È University Hospital, Sweden. They were all found to consist of normal benign and hyperplastic prostate glands at histopathological examination. Malignant specimens were obtained at TURP from six patients with previously known cancer of the prostate (CAP), representing WHO grade 1 (n 1), grade 2 (n 2) and grade 3 (n 3). Within 30 min after collection, the tissue specimens were immersed in either 4% paraformaldehyde (PF) overnight or in Bouins' solution for 4 h and embedded in paraf®n as previously described. 24 Tissue sections of 4 mm in thickness were mounted on Superfrost Plus w slides (Menzel-Gla È ser, Germany) and dried at 60 C for 60 min, deparaf®nised in Xylene and rehydrated in decreasing ethanol concentrations prior to IHC. The Helsinki Declaration regarding the use of human tissues was strictly observed in all cases.
Monoclonal anti-PSA and anti-ACT IgGs
The previously characterised speci®c monoclonal IgG antibody preparation (Mab) against PSA, code number 2E9, is known to recognise the free form of PSA and PSA in complex with ACT. 18, 26, 27 This Mab has been used in immuno¯uorometric measurement of PSA in serum 18 and in histochemical studies, both in conventional IHC 24, 25 and as recently described in TRFI. 14 For detection of ACT, we employed an earlier described monoclonal IgG preparation (code 2G7) known to detect continuous epitopes accessible on both puri®ed ACT and ACT complexed to PSA. 20, 24 Labeling of anti-PSA and anti-ACT Mabs with lanthanide chelates Fluorescent chelates of Eu (W1024) and Tb (W14016) and all reagents in the labeling procedure were generous gifts from Wallac OY (Turku, Finland). Labeling of the 2E9 and 2G7 Mabs with Eu and Tb, respectively, were performed according to the instructions of the DELFIA Eu-labeling kit with minor modi®cations. Brie¯y, the reactions were carried out in 0.05 M carbonate buffer (pH 9.8) at 4 C for 18 h using 100 ± 2006molar excess of the chelates. The labelled Mabs were separated from free chelates by size fractioning using a Superdex w 200 HR 10a30 column in an FPLC system (Pharmacia, Uppsala, Sweden) with 50 mM Tris-HCI, 0.9% NaC1, 0.05% NaN 3 as elution buffer. The labeling degrees (Eu-or Tb-chelatesaIgG) were determined using standard solutions to calculate the Eu-and Tb-concentrations, and either corrected absorbance at 280 nm (for Eu) or absorbance at 600 nm after the addition of Bradford's reagent 28 (for Tb) to measure the protein concentration. When measuring the Tb-concentration, the samples were incubated in 0.1 M HC1 for 10 min to free all Tb chelates, before the addition of DELFIA enhancement solution. Finally, diethylenetriaminepentaacetic acid (DTPA)-puri®ed BSA was added to ®nal concentration of 0.1% and the solutions ®ltered through a 0.22 mm ®lter (Millipore, Bedford, MA). The labeling degree of the anti-PSA Mab 2E9 was 9.2 Eu chelates per IgG and for anti-ACT Mab 2G7 it was 3.7 Tb chelates per IgG.
Direct immuno¯uorescence with lanthanide chelates
After dehydration, the paraf®n sections were rinsed three times in 50 mM Tris-HC1 pH 7.6 with 0.8% NaC1 (TBS, Tris-buffered saline). Following a weak background staining with Accustain Hematoxylin solution Gill No 1 (Sigma Diagnostics, St. Louis, USA), diluted 1:80 in distilled H 2 O for 5 min and rinsing63 in TBS, the anti-PSA and anti-ACT Mabs were applied in TBS with 2% BSA (Sigma) for 4 h at room temperature. The working concentrations used were determined from a dilution curve, obtained after incubation of adjacent tissue sections with increasing concentrations of lanthanide conjugated Mabs; 2G7: 0.9 ± 29.4 and 2E9: 0.7 ± 46.5 mgaml. Final working concentrations were chosen from beginning of the plateau phase of the respective curve corresponding to when saturation of the epitopes was reached ( Figure 1 ). 2E9-Eu was then used at 23.3 and 2G7-Tb at 14.7 mgamL for the subsequent analyses. For double labeling purposes, a mixture of Eu-labelled 2E9 and Tb-labelled 2G7 was applied simultaneously for 4 h. The slides were again rinsed63 in TBS and dehydrated in decreasing concentrations of ethanol, xylene and ®nally mounted in Merckoglas w (Merck, Sharpe & Dohme, Darmstadt, Germany) using 1.5 mm thick cover slips (Menzel-Gla È ser) and stored in the dark at 4 C. The speci®city of the immunoreactions was veri®ed by substituting the anti-PSA or anti-ACT Mab with buffer solution. Both PSA and Act Mabs have been shown to be speci®c for their respective antigens as demonstrated earlier. 26, 27 
Indirect immuno¯uorescence with¯uorescein isothiocyanate (FITC)-labelled rabbit anti-mouse IgG
In order to compare TRFI with conventional immunouorescence, tissue sections were incubated overnight with anti-PSA Mab (2E9) or anti-ACT Mab (2G7) (both at working concentration 5 mgamL) using a conventional indirect immuno¯uorescence method. 29 FITC-conjugated rabbit-anti-mouse IgG, diluted 1:20 (code F313, Dakopatts, Glostrup, Denmark) was used as secondary antibody. PBS pH 7.4 was used as buffer throughout the processing. Finally, coverslips were mounted in an 1:4 (by weight) mixture of 0.05 M Tris-HC1: glycerol buffer, pH 8.6.
Time-resolved¯uorescence imaging (TRFI)
TRFI was performed as recently described, 14 but with some modi®cations. Brie¯y, a Nikon Optiphot w conven-tional epi¯uorescence microscope (Nikon, Tokyo, Japan) was equipped for TRFI as originally described 10 and modi®ed according to Rulli et al. 13 Using a 106objective, the tissue sections were focused on bright-®eld mode with a conventional halogen light source to avoid signal bleaching. A xenon¯ash lamp (60 W, arch length 1.5 mm, 500 Hz) (EG&G, Princeton, NJ) was used for pulsed excitation at 340 nm wavelength (coloured glass ®lter DUG 11, 320-390 nm, Schott, Mainz, Germany) and a highly sensitive stable and high dynamic range camera (model 1530-AaAUV, EG&G) was used as a cooled charge coupled photo-optical device (CCD) with dark noisè 0.1 electronsapixelas, where the size of 1 pixel is 23623mm. The following conditions were used for detection of Eu-chelate luminescence: emission wavelength 615 nm (7 cavity bandpass ®lter, 7 nm widthness, BARR Assoc. Inc. Westford, MA), excitation pluse length 1 ms, pulse energy 0.4 Japulse, delay time after excitation 300 ms, detection period after excitation 1200 ms, repetition frequency of excitation and detection 500 Hz and measurement time 29 s. For detection of Tb-induced uorescence, an emission ®lter at 545 nm was used instead (BARR). When the prompt imaging mode for conventional indirect immuno¯uorescence (FITC-labeled secondary antibodies) or lanthanide chelate (Eu or Tb)-induced¯uorescence was used, the camera was exposed during the whole excitation period, but the light source, pulse length and energy were the same as used for TRFI. For detection of FITC-induced¯uorescence, a FITC HQ®lter block (Chroma Technology, Brattleboro, VT) was used and the exposure time was 4 s.
Image data was collected with the cooled CCD-camera and the subsequent image analyses employed an interactive image processing software, Iedit v. 09 beta (Wallac).
Fluorescent signals in tissue sections could be roughly estimated using the pseudocoloured intensity bar ( Figure  2 ). The intensity bar is put together using collections of the pixel intensities from the whole image area leaving out 10% of the lowest and 10% of the highest signals. The pictures were pseudocoloured using the software Waliant (Wallac) and Picture Publisher 7 w (Micrografx, Inc. Richardson, Texas) was used to insert the intensity scale.
Quanti®cation of signals
For quantitative analysis, dilution curves were created for both lanthanide chelate-conjugated Mabs in incubation buffer (50 mM Tris-HC1, pH 7.6, 0.8% NaC1, 2%BSA) ( Figure 3 ). Increasing concentrations of both Mabs (2E9-Eu: 1.5 ± 9.3 mgaml, 2G7-Tb 1.2 ± 29.4 mgaml, 5 replicas of each dilution) in TBS 2% BSA were pipetted in 0.3 ml drops (Eppendorf Research pipette, range 0.1 ± 2.5 ml, Hamburg, Germany) on Superfrost Plus w slides, airdried at RT and mounted in Merckoglas w . Drops of buffer were used as background. One concentration was chosen from the middle of the linear dilution curve ( Figure 3 ) and ten more replicas of that concentration were analysed to get a reliable mean value for calculations. Measurement of whole drops was done with a 46objective. The number of counts per pixel detected with the 106objective were 28.2 times higher than using the 46objective (average based on ten measurements with 2E9-Eu and 2G7-Tb chelates on tissue sections as well as in drops), due to a more intense excitation and more ef®cient signal collection with the 106objective.
The¯uorescence intensity was determined on the computer screen as the mean signal (counts per pixel, cpp) detected per drawn region of interest, usually a group of tumour cells or a glandular structure omitting the lumen. The speci®c intensity used in the analysis was calculated as the difference between the average signal in the drawn area minus the background signal obtained from measuring the average signal in the stroma surrounding the glandular structure.
Results
Paraf®n sections of benign and malignant prostate specimens, ®xed in Bouin's solution or paraformaldehyde Time-resolved¯uorescence imaging of PSA and ACT A Bjartell et al were examined for lanthanide chelate-(Eu or Tb) or FITCinduced immuno¯uorescence in a TRFI system. When prompt imaging mode (pulsed excitation with continuous signal detection) was used, disturbing unspeci®c tissue auto¯uorescence made it impossible to clearly visualize and measure only the speci®c¯uorescence. Using timeresolved¯uorescence mode, only speci®c signals were detected as fast decaying unspeci®c tissue auto¯uores-cence was avoided when the counting time begun 300 ms after every excitation pulse. FITC-induced¯uorescence in indirect IHC showed a similar staining pattern accomplished with unspeci®c tissue auto¯uorescence, although the primary Mabs (unlabeled 2E9 and 2G7) were used at a lower concentration (5 mgaml) (not illustrated). An overview of the immunostaining pattern in TRFI was easily obtained when a pseudocoloured image was generated, as the colours could be related to an intensity scale (Figure 2) . Some of the PSA containing cells did not show any immunoreactivity for ACT and vice versa. However, PSA and ACT were to some extent detected in the same cells in benign prostatic glands and in tumours as described earlier, but in the typical BPH nodule, immunoreactive ACT was rarely detected. Immunoreactive ACT displayed a cytoplasmic immunostaining pattern, but ACT was not predominantly located apically in the cells as PSA was (Figure 2 ). PSA was immunodetectable in all tissues examined except for one poorly differentiated tumour. The same tumour and a moderately differentiated tumour, did not contain any measurable signals from Tb-labelled anti-ACT Mabs.
Quantitative IHC by TRFI
Tissue sections could be focused by the halogen light source in bright-®eld mode up to 1 min without signi®-cant (`5%) loss in signal intensity (data not shown). In negative control sections, that is, incubation with buffer as replacement for Mabs, detection of¯uorescence at 615 nm (Eu) yielded less signals (measured in cpp) than at 545 nm (Tb), but no obvious difference in signal level was observed between paraf®n and Bouin's-®xed tissues (Table 1) . Near saturation concentrations of Mabs were applied for both separate use and dual-labeling on the same tissue section. The construction of dilution curves of drops with a known amount of Eu-or Tb-labelled Mabs (Figure 3) , enabled us to calculate the amount of bound Mab per pixel in areas of glandular epithelium or tumour cells of immunostained sections. For these estimations, we utilised the amount of IgG in drops, the mean uorescence intensity of drops, the molecular mass of IgG and the correction factor between the 46and 106objective (628.2) as described above. From each section, several areas (n 10 ± 35) corresponding to glandular structures or tumour cells were analysed. Using 2E9-Eu, 1 cpp corresponded to 5.1 fmole per pixel (fmoleap), and for 2G7cpp was determined as 63 amoleap of bound IgG in a tissue section. The calculated concentrations of bound IgG in the tissue sections showed substantial variation. The highest values detected for PSA and ACT Mabs were 7.2 and 27.3 fmoleap, respectively and were found in a section of benign prostatic epithelium (Table 2) . In tumour specimens, the highest values were found at a lower level. Generally the amount of ACT was usually higher than that of PSA, but the opposite was also found (Figure 2) . Data from the dual-label stainings on benign and malignant tissue is given in Figure 4 . There was no obvious correlation found between the staining with anti-PSA and anti-ACT Mabs as judged from our limited material. In all tissues examined, the ratio of bound IgG per pixel for ACT compared to PSA varied between 0.4 and 41.7 but there were also many areas without any immunodetectable ACT (Table 2 , Figures 2 and 4) .
Discussion
This present study describes a novel method for dual detection and quanti®cation of PSA and ACT in prostatic tissue sections employing TRFI. The properties of lanthanide chelate-induced¯uorescence as described above, make Eu and Tb suitable as labels in immuno¯uorometric assays 1,2 but still they are not that widely used in histochemistry. The indirect immuno¯uorescence method for TRFI with Eu-conjugated streptavidin, was quite recently described as a simple and reproducible technique to detect PSA in tissue sections. 14 We have now developed a direct quantitative immuno¯uorescence method, which enables dual-labeling and measurement of two antigens. Again, there is no need for frozen sections as paraf®n sections of both PF or Bouin's ®xed tissues work well. The thickness of the tissue sections is crucial for the quantitative measurements and we have standardised it to 4 mm.
The protocols for the direct as well as for the indirect IHC method are less complicated than for conventional IHC. Comparison with FITC-induced immuno¯uores-cence and analyses in prompt vs time-resolved mode, con®rmed that unspeci®c tissue auto¯uorescence is successfully avoided in TRFI. The working concentrations of the used Mab is also important, and should be balanced between saturation and unspeci®c binding due to excess of antibody. There were clearly detectable signals already at concentrations near the level used in convential IHC with the highly sensitive APAAP-method 24 and FITCmethod for indirect IHC as described above, but for quantitative IHC saturation is of utmost importance (Figure 1) . It is not possible to determine the Mab concentration when saturation is reached in the FITC-method and a working concentration of 5 mgaml is only a rough estimation based on visual examination.
Besides the detection of speci®c¯uorescence without disturbance of tissue auto¯uorescence, another advantage with TRFI is the linearity of the signals (Figure 3) . The conjugation of Mabs with chelates of Eu or Tb then makes it possible to estimate the amount of IgG bound per pixel in tissue sections ( Table 2 ). The Eu-chelate (conjugated to the anti-PSA Mab 2E9), is superior to the Tb chelate (used for labeling of the anti-ACT Mab 2G7) in sensitivity, and the values of ACT in many glandular areas were below the sensitivity level. Although the Tb-chelate used in this study works well, a more sensitive Tb-chelate is required to improve the detection level of this immunodetection assay.
The synthesis and localisation of ACT in benign and malignant prostatic tissue have been reported by our and other groups 24, 25, 30 and recently, a cDNA for ACT was also cloned from prostatic tissue. 31 In blood, ACT is the predominant inhibitor of PSA and approximately 80% of serum-PSA is usually bound to ACT. However, there is a difference in the degree of complex formation in patients with either CAP or BPH, which has been used to increase the speci®city of PSA as an indicator for CAP. 18 ± 23 Exactly where the PSA-ACT complex measured in blood is formed is still unknown. Physiologically, a complex formation seems reasonable to occur when PSA leaks from the epithelial cells into the stroma, as PSA is described to be a proteolytic enzyme. 32 Recently, the concentration of PSA-ACT complex was suggested to be an important serum marker as it correlated to prostate cancer. This hypothesis was supported by Chen et al, 33 who demonstrated the occurrence of PSA-ACT complex in CAP but not in benign epithelium as shown by IHC with a speci®c Mab against the complex. The same group have also reported that PSA predominantly occurs in a cleaved enzymatically inactive form in uid from BPH nodules. 34 In this present study, WHO grade 1, 2 and 3 tumours (low, medium and high in differentiation grade), were examined but this limited series (n 5) is too small for statistics to be applied on. It does, however, indicate the TRFI can be applied on larger series to generate quantitiative histochemical data, that has not been possible with currently available technologies.
The lack of correlation between PSA and ACT ( Figure  4 ) is in accordance with previous reports 24, 25 and re¯ects that PSA and ACT seem to be regulated by different factors.
Conclusions
TRFI offers an attractive method for histochemical studies because of its extended linearity without disturbing tissue auto¯uorescence. This dual-label TRF method for direct IHC enables quantitative comparison of two antigens even at an intracellular level. The use of¯uorescent lanthanide chelates in ISH studies, provides an attractive alternative to well established techniques. 10 Department of Clinical Chemistry, Lund University, Malmo È University Hospital, Sweden, for their expert technical assistance. Petri Aronkyto È , Wallac OY, Turku, Ari Kuusisto, Ilkka Hemmila È and Airi Toivonen, Department of Biotechnology, University of Turku, Finland are also greatly acknowledged. The study was supported by generous grants from the Swedish Medical Research
